We Thanks, years. our Robert, Taveira, Directors well last appreciation of served of by to as afternoon, today extending have XX and to been last thanks good our and our hope a who company's like safe Paul you call. everyone. and for start I'd ably since the member Board
a and insights direction. Paul guidance to strategic the As helped trusted provided for long team Lannett. Paul shape the thank management to and his service company's adviser, We
members, X For reelected now, our X all Board were Meeting last of held at versus our whom Annual will X Shareholders consist of week.
Turning to a financial recent in November. update then the developments assets to begin I'll business. provide portfolio. quarter I'll our on progress with context pipeline, second plan restructuring we results, the durable related in company more discuss on our including announced some then our
have pricing generic in we industry last over has competitive. the As discussed environment exceptionally the few quarters, been the
supply analysts alike, This independently to priced and reported intensified phenomenon, competitively has and our competitive generic a by expect, beyond as contributed, customers portfolio internal this pricing you drug related be sales sector. estimates. base gross covering in historical number with market to that Lannett already supply the for number The find environment currently deteriorating industry-wide prescription reliable well key believe of expanding and and ourselves recent been help incremental has our newer on. generic pressure of A to step and important fewer may we for pricing customers and is capitalize relatively has been the We products. supply opportunities that based the price positioned predominantly reasons would environment which margin the situation, approvals net products. Thus, we U.S. and our A oral chain the higher effect approvals primary our disruptions. expectations. for in there and norms obviously competitive of While launches were lower on is to are of lower research knock-on manufacturers to few an effect particularly across cause related is than products, of a fewer perhaps to experienced of and older
While notably the fiscal we expectations we opportunities business will have this our such over believe with year. of reemerge, time, such balance reduced for
pandemic, year, unexpected this dose discuss to a issues, which appear merely John API stress, finished to In back supply markets launch episodic disruptions certain supplied are pushed sitting we however, watching the not pipeline been events the products have do I back moment, while suffered well have sevoflurane. in we remarkably lines we that Finally, more had for during or have including detail. zolmitriptan will unfold. and expected numbers the that time
mitigate In fact, have the to several of continue impact the we take actions environment. and to pricing current
I partnerships. greater First, this to and new in pipeline, by shortly. will adding organically both value-adding detail products discuss through our
increase by and to of our being productivity Second, upon. will that even looking development also pipeline our in selective elaborate the more I profitability processes,
supply reducing possible vigilantly customers fourth, And and supply disruptions and USA to Third, reliable continue costs revenues. chain plan. execute while and generating by prepared remaining helping and where cost-reduction predominantly by restructuring to and opportunistically valuable to leverage chain when upon a address our
needs same launch which support on key believe also pipeline remains ready importance performance. durable since scope positions for we a our adequate durable remain growth our of products, we Maintaining our At to opportunities for of the improved focus. of and emphasized levels continue cash of position. of these the more Concurrently, company we the strategy While operational we pipeline cash our our to the the be advancing emerge. to and predicted, time, timing them cannot execute
our XX, position reference, cash approximately $XX of point a December at As million was XXXX.
completion, plan, restructuring $XX Turning will and we upon of generate to the approximately million expect, cost-reduction savings. which
and year. We With R&D internal reducing be the we fiscal initiatives of current regard with at which associated function, largely we and first, the completed completed plan streamlining of those included progress, excellent and end headcount the initiatives, to eliminating development are our making the the by anticipate where have have will we seen contract liquid Carmel, our savings future of same we to development declining some discontinuing the overseas efforts. to augment the into programs medications, site further New returns reinvest inadequate York justify the cost lower development and At internal to investment. intend time, scale generic targeting
Second, levels we the have have staff corporate redistributed. reductions consolidated and mentioned. organization, the Certain been Trevose, been Pennsylvania. functions have throughout including examined, the at completed even targeted Seymour, workloads organization as board headcount plant All of and level, previously Indiana to headquarters our in
phasing Carmel the sites. we've out Seymour and of products certain begun production low-value both the Third, identified and at
completed transferring routine fiscal advanced the Seymour. technical And liquid transfers, in main among certain our discussions have We requires, from of to Carmel The process finally, Seymour also we regulatory clearances take manufacturing fairly Carmel effort facility to begun our process this the plant. and sale products and some have at other our investment things, complete. of into XXXX estimate sale our in a We and will site former facilities time equipment of for operating of the plant. plant the modest our Wyoming Cody, in
transfer owner product as agreement the will would near We that in aforementioned for work certain for a a new We'd well and site Carmel facilitate definitive the expect largely future. sign as of are retain time. production employment we the optimistic period
of related restructuring by the phases, year. some and the Having said fiscal end expect will by we actions will to see current savings in the be said, previously have plan cost quarter completed of be the we most year. this that, As fourth fiscal implemented
our Now let's to pipeline. turn
durability addressing regular our competition. of quarter, time and significant last lot the medications, spent diversified subject these of to the we due time opportunities respiratory the value Nevertheless, other those a Stadol and we to also energy noted scale, in immediate-release beyond assets. forms As insulin biosimilar increasing and dosage invest potential
come Given the articulated to have on a the pressure year products more current focus of will ahead that on larger our on. market assets portfolio, typically next bit color we we we provide may
million successful fiscal an looking expected including So was are inspection launch action which to our to solution pushing lower. to be contribution to year. amendment August margin A launch millions subsequent date for to expected a is sevoflurane, the other our year, current the fiscal currently. providers facility market double-digit are product in-market gross sales in working We $XXX Sevoflurane we this four inhalation. low generic meaningful is XXXX. are API is several to sevoflurane next expectation roughly this target although had but There according to IQVIA, XXXX, made, products, for
advancing studies. addition zolmitriptan, sevoflurane bioequivalent which the aforementioned we nasal fairly sucralfate is In also our are suspension, oral has a difficult vitro and in generic a spray, which to
year. fiscal a Lialda single review, discussions has we a dollars. challenging existing quarter. the the file to to gross contributions with If low in expect contribution an program. We Generic a achieve product or It generic margin cycle has in are first also high Lialda begin partner. secure double-digit development may millions next of potential we advanced this Moreover,
Our existing to we product our dollars, of year. launch within generic again file some months. the CHANTIX that could Full product the gross is contribution possible partner high double-digit add year portfolio soon margin millions in few to expects are next a year. and to and be next we'll low single the next of optimistic Similarly, the that
of which for expansion [indiscernible] into China. is is the and collaboration, brand the advancing sold we're our Nuance produced we However, which
dollars manufacturing That for We to profits in the have contract our next China a of FDA fairly unique work year. add plant. approval might millions from our mid-single-digit U.S. organization expanding
reliable we have manufacturing and high-quality the to site. and such as plant, Given excess are a believe now leverage contract just we scratching generic surface manufacturing our its opportunities Seymour on capacity we value development our beyond plant at
to is of don't For hard manufacturing, The them year accessible, in our but fire," of every continue have culminated, be those know the to we reliable seeking we unabated next we high-quality We and do through of this ways the assets. that team point looking have to also working trends pharmaceutical opportunity make you is such don't current and way. leverage and and our been all our listening will happen. expect send "irons for that easily that many firms expect development
emphasizing impacted in less areas increasingly also, for some We regular the solid oral been generics. have by time, commoditized development portfolio
While including products plus aspirations, pending we internal pursue have pending with have we continued XX Overall, FDA, that and we opportunities. ANDAs still additional to core and insulin approved business four in external launch. both the our value transformational products partner are at invest strengthen our to
products We strategy development also have a and dozen review. under more in about
to to efforts. from pipeline As our internal external noted above, and we expect more add
with generic three our products commercialization. now I'll Turning to with start respiratory The to product partner Diskus. durable closes currently Respirent. Advair
last disciplined our review call on comments in FDA November, the on pending discussed the we ANDA. provided As mid-cycle
the of engagement. comments level delighted their continue agency's and respond We and have with to to remain and requests
goal month moved related However, the an of amendment. has FDA-assigned the date the end to API to
to product our cycle. early before We launch in we for than more that the expect further can feedback or a refine undergo we year FDA this expectations. await As one possible we are previously XXXX, planning disclosed, is but believe later and review calendar
We our approval ANDA combination referencing also Diskus. call, note that who salmeterol, and dry since promotes already powder an a of inhaler fluticasone of received a Advair Teva, last
We was under they FDA Meanwhile, earlier have a their we of Cipla approval XXXX. fiscal are not in that an filer aware earnings review plans. noted and other targeting the file only heard calls were has in commercialization their of, their
this XXX The We last respiratory microgram on a microgram a results and our PK summer generic trial, XXX begin PK trial PD initial second most the XXX in completed Flovent favorable pipeline should successfully product advanced a the trial is subject month. for Diskus.
are currently early ANDA fiscal We next an year. planning submission
development calendar Handihaler for We months Regarding pilot our to year. product. Spiriva behind approximately generic this product initiate the should XX this partner look a be Diskus art Flovent PK later Respirent, generic with the
glargine, the FDA two long-acting about of IND new we Next, the six HEC. with proposed insulin insulin we the the weeks the our that concluded with ago, application announced a we the of regarding with drug announced an ago co-developing proceed clinical biosimilar weeks and FDA submission completed investigation. partner, may are review product About safety investigational and we
the XX% interchangeability approved clinical and We insulin nearer. completed product market and will opportunity the launching expect sales to worth in penetration. We by the we month next we a if application will The remains year's sales, by contribute supply, is and the annually approximately is shortly contribute glargine product net commercial significant XXXX. accelerate the FDA, early the pivotal the $XXX license sales. to thereafter time believe and, we would be won't could early filing have think commence million trial access successful, next which trial next is for capacity to So we potentially share, certainly while the anticipate by believe drawing year. anticipate biologic to If it
product that behind fast-acting insulin Development HEC. The biosimilar are a pipeline, this bit insulin approximately of more co-developing aspart, is second with insulin a we product also than glargine. year is insulin in one our
already is worth of commercial they sales. believe next to analytics partner scale in first half a net an Our file a have producing already, as market aspart proceed we'd assuming excess calendar the million XX% the product in is IND share We of $XXX year. market and expect of at insulin in
Finally, our has activity been subside. pandemic for team development as picking business up restrictions
the some the In call performance, new manufacturing, review these of and opportunities in John? traditional to share we hope partners successes soon. addition authorized areas asset often in over established monetization. product pleased injectables, We in-licensing, our I'll to contract to John are be seeing financials. with other also turn to to generics with able now types
